1. Introduction {#sec1}
===============

Contrast-induced acute kidney injury (CI-AKI), also referred to as contrast-induced nephropathy (CIN), is an iatrogenic complication that can occur following intravascular administration of iodinated contrast medium (CM) prior to radiography. CI-AKI is the third leading cause of hospital-acquired acute renal injury (AKI) \[[@B1]\]. CI-AKI has a low incidence in the general population, but it has a significant incidence in patients with certain risk factors. Moreover, the occurrence of CI-AKI following cardiac catheterization procedures is associated with an in-hospital mortality of 20%, a 1-year mortality of up to 66%, and an even higher mortality in patients who require dialysis \[[@B2], [@B3]\]. However, even if patients with high risk of CI-AKI can be identified a priori, no known pharmaceutical treatment can effectively prevent or treat CI-AKI.

Guidelines recommend intravascular hydration to prevent CI-AKI \[[@B4], [@B5]\], and there are several specific hydration strategies, but researchers have not yet established an optimal strategy \[[@B6]--[@B9]\]. Notably, recent randomized controlled trials (RCTs) have led to doubts about the effectiveness of various hydration strategies in prevention of CI-AKI. For example, Nijssen et al. \[[@B10]\] conducted an RCT with 660 high-risk patients and found that no prophylaxis was noninferior or cost-saving relative to intravenous hydration. Weisbord et al. \[[@B11]\] enrolled 5177 high-risk patients and reported no benefit of intravenous sodium bicarbonate relative to normal saline. Another RCT \[[@B12]\] concluded that the benefit of sodium bicarbonate was marginal relative to isotonic sodium chloride for preventing CI-AKI among critically ill patients. However, other studies indicated that the RenalGuard System \[[@B13]--[@B16]\] and hemodynamic guided hydration \[[@B17]--[@B19]\] were safe and effective in preventing CI-AKI. Because of these apparently discrepant results, we conducted a network meta-analysis (NMA) to assess the effects of various hydration strategies on the occurrence of CI-AKI in an effort to identify the optimal strategy for prevention of CI-AKI.

2. Methods {#sec2}
==========

2.1. Data Search {#sec2.1}
----------------

This systematic review and meta-analysis were performed according to Cochrane Handbook guidelines \[[@B20]\]. The Web of Science, PubMed, OVID Medline, and Cochrane Library databases were searched using medical subject headings or keywords. Relevant published original studies that were published up to September 30, 2018, were examined. The search syntax was as follows: "contrast-induced acute kidney injury OR contrast-induced nephropathy OR CIN OR CI-AKI OR contrast acute renal failure OR contrast nephropathy" AND "hydration OR fluid administration OR volume expansion OR intravenous sodium bicarbonate OR saline infusion."

2.2. Study Selection {#sec2.2}
--------------------

An initial eligibility screen of all citations was conducted, and only studies that examined CI-AKI and hydration were selected for further full-text review. All included studies were RCTs; experimental studies were excluded. In addition, all included studies reported the prevention of CI-AKI after intravascular administration of CM; used clinical protocols that were hydration strategies, not pharmaceutical prevention strategies; had clear definitions of CI-AKI; and provided data on the outcome of interest (occurrence of CI-AKI within 2 days to 1 week after procedures).

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

Two authors (C. Q. P. and J. R.) independently reviewed each article for eligibility. Any disagreement was resolved by discussion among the authors or involvement of a third author. Data extraction included the year of publication, sample size, patient characteristics, risk factors associated with CI-AKI (old age, diabetes mellitus, renal impairment, heart failure), and type and dosage of contrast medium. The primary endpoint was the occurrence of CI-AKI within 2 days to 1 week after intravascular administration of CM. Two investigators independently evaluated the quality of each study using the Jadad scale, which ranges from 0 (worst) to 5 (best) \[[@B21]\].

2.4. Statistical Analyses {#sec2.4}
-------------------------

The advantages of Bayesian NMA over traditional meta-analysis are its greater flexibility, its provision of more naturally interpretable results, and its ability to rank treatments by comparative effectiveness \[[@B22]\]. The occurrence of CI-AKI as a dichotomous outcome variable was expressed as an odds ratio (OR) and 95% confidence interval (CI). All *P* values were 2-sided, and a *P* value below 0.05 was considered significant. All analyses were conducted using the Bayesian Markov chain Monte Carlo method in WinBUGS V.1.4.3 (MRC Biostatistics Unit, Cambridge, United Kingdom) using the Microsoft Excel-based macro NetMetaXL V.1.6.1 (Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada) \[[@B23]\]. A convergence test for each analysis was conducted by checking whether the Monte Carlo error was less than 5% of the SD of the effect estimates or the variance between the studies. Convergence was achieved for all analyses using 1000 "burn in" runs and 1000 model runs. NetMetaXL was also used to generate a forest plot, league table, and "rankogram" with surface under the cumulative ranking curve (SUCRA), which ranges from 0 (worst) to 100% (best). Inconsistency was assessed by comparing the residual deviance and deviance information criterion statistics in fitted consistency and inconsistency models.

3. Results {#sec3}
==========

3.1. Literature Search {#sec3.1}
----------------------

We initially identified 3620 publications, assessed 703 RCTs for eligibility by review of the full texts, and ultimately included 60 RCTs which met the eligibility criteria ([Figure 1](#fig1){ref-type="fig"}). These studies examined 21,293 patients (median: 222, interquartile range \[IQR\]: 120, 350) and 2232 CI-AKI events. All included RCTs were full-length journal articles. Agreement between the two reviewers at the full-text review stage was excellent (Cohen\'s *κ* = 0.85).

3.2. Characteristics of Studies and Participants {#sec3.2}
------------------------------------------------

[Table 1](#tab1){ref-type="table"} shows the characteristics of the included studies. The publication date ranged from 2002 to 2018, and about 50% of the studies were published after 2013. The proportion of male patients ranged from 25.0% to 98.1% (median \[IQR\]: 65.7 \[56.9, 74.8\]), and the mean age ranged from 56.2 to 82.9 years (67.8 \[63.1, 72.5\]). Thirty-one studies enrolled 12,519 patients who had high risk of CI-AKI. The baseline serum creatinine (SCr) level ranged from 61.4 to 236.4 *μ*mol/L (117.1 \[89.5, 136.9\]), and the baseline estimated glomerular filtration rate (eGFR) ranged from 32 to 93.1 mL/min/1.73 m^2^ (49.2 \[44.1, 74.2\]). Twenty-three studies provided the values of left ventricular ejection fraction (LVEF); the mean LVEF ranged from 25% to 57.8% (49.0 \[42.8, 54.5\]). The percentage of diabetes mellitus (DM) patients ranged from 8% to 100%, and the percentage with heart failure (HF) ranged from 0.6% to 45.8%. A total of 8176 patients from 32 studies received intravenous low-osmolar nonionic CM, 9993 patients from 17 studies received iso-osmolar nonionic CM, and 317 patients from 2 studies received low-osmolar ionic CM. The mean Jadad score of the 60 RCTs was 3.2 (3 \[2, 4\]), indicating the overall study quality was good.

3.3. Network Meta-Analysis {#sec3.3}
--------------------------

[Figure 2](#fig2){ref-type="fig"} shows all the comparisons in the NMA. Thirty-seven studies (13,365 participants) compared the efficacy of intravenous sodium bicarbonate and 0.9% sodium chloride. The other hydration strategies were nonhydration (8 studies, 1396 patients), oral hydration (6 studies, 355 patients), intravenous half iso-osmolar saline (3 studies, 968 patients), intravenous hydration, mainly normal saline + diuresis (2 studies \[[@B26], [@B31]\], 501 patients), hemodynamic guided hydration (3 studies, 458 patients), and RenalGuard system guided hydration (4 studies, 348 patients).

We compared the ORs of the different hydration strategies using a forest plot ([Figure 3](#fig3){ref-type="fig"}) and analyzed the results of the random effects consistency NMA using a league table, which shows all pairwise comparisons ([Figure 4](#fig4){ref-type="fig"}). Taken together, these results indicate that, relative to typical intravenous 0.9% sodium chloride hydration (reference), the occurrence of CI-AKI was significantly reduced by intravenous sodium bicarbonate (OR \[95% CI\]: 0.74 \[0.57, 0.93\]), hemodynamic guided hydration (0.41 \[0.18, 0.93\]), and RenalGuard system guided hydration (0.32 \[0.14, 0.70\]). Oral hydration (0.72 \[0.28, 1.82\]) and intravenous 0.9% sodium chloride (0.64 \[0.39, 1.08\]) were each noninferior to no hydration for prevention of CI-AKI. Relative to oral hydration (reference), intravenous 0.9% sodium chloride or sodium bicarbonate and hemodynamic guided hydration were each noninferior in prevention of CI-AKI, but RenalGuard guided hydration was superior (0.21 \[0.07, 0.63\]). Intravenous hydration plus diuresis also did not decrease the risk of CI-AKI relative to oral hydration and no hydration.

A rankogram and SUCRA values indicated the RenalGuard system was best (SUCRA = 0.974) followed by hemodynamic guided hydration (SUCRAs = 0.849; [Figure 5](#fig5){ref-type="fig"}). Intravenous sodium bicarbonate had a SUCRA of 0.667. The SUCRAs for intravenous 0.9% sodium chloride, intravenous hydration plus diuresis, oral and no hydration, and the other treatments ranged from 0.197 to 0.441, and their rankings were similar. Hydration using half iso-osmolar saline alone was the least effective treatment.

3.4. Inconsistency Analysis {#sec3.4}
---------------------------

We performed network inconsistency assessment for the fixed effect model for the 60 studies ([Figure 6](#fig6){ref-type="fig"}). The resulting plot demonstrated that nearly all the studies were near the line of equality and that the results were therefore consistent. However, there was some evidence of inconsistency in 3 noninferiority studies \[[@B10], [@B31]\]. In particular, Martin-Moreno et al. \[[@B31]\] and Nijssen et al. \[[@B10]\] found that intravenous sodium bicarbonate and 0.9% sodium chloride were noninferior to oral hydration.

4. Discussion {#sec4}
=============

To our knowledge, this is the first NMA to compare different hydration strategies for prevention of CI-AKI. We included 60 RCTs which examined 21,293 participants and 2232 CI-AKI events. Our comparison of 8 hydration strategies for preventing CI-AKI confirmed that, relative to intravenous 0.9% sodium chloride hydration, three treatments during CM administration significantly reduced the risk for CI-AKI: the RenalGuard system, hemodynamic guided hydration, and intravenous sodium bicarbonate. Relative to no hydration, oral hydration and intravenous 0.9% sodium chloride were each noninferior in prevention of CI-AKI. Relative to oral hydration, intravenous 0.9% sodium chloride and sodium bicarbonate were each noninferior in prevention of CI-AKI. Thus, we ranked the RenalGuard system as the best strategy and hemodynamic guided hydration as the second best.

Guidelines for the prevention of CI-AKI in high-risk patients routinely recommend hydration protocols before contrast exposure as an established preventive measure \[[@B77], [@B78]\]. A recent large RCT \[[@B10]\] led us to reanalyze the efficacy of hydration for prevention of CI-AKI. In particular, the AMAstricht Contrast-Induced Nephropathy Guideline (AMACING) study \[[@B10]\] enrolled 660 patients with high risk of CI-AKI and concluded that, relative to intravenous hydration, no prophylaxis was less expensive and noninferior in prevention of CI-AKI. In our meta-analysis, five studies compared the effectiveness of intravenous 0.9% sodium chloride and three studies compared bicarbonate with nonhydration, leading to our conclusion that, relative to no hydration (reference), oral hydration or hydration with intravenous 0.9% sodium chloride was noninferior in prevention of CI-AKI. These results were unsurprising, because simple oral or intravenous hydration can lead to complications, such as heart failure, pulmonary edema, and electrolyte disorders. Thus, the safety window of hydration is relatively narrow for patients undergoing percutaneous coronary intervention (PCI), and other more effective or precise hydration strategies may be needed to decrease the incidence of CI-AKI.

Most meta-analyses before 2016 \[[@B79]--[@B83]\] confirmed that intravenous sodium bicarbonate was more effective than sodium chloride in preventing CI-AKI. However, two recent influential studies concluded that intravenous sodium bicarbonate provided no benefit over intravenous sodium chloride in high-risk patients \[[@B11]\] and critically ill patients \[[@B12]\]. Our NMA included 37 studies that compared intravenous sodium chloride with sodium bicarbonate, and our results also indicated that intravenous sodium bicarbonate led to a reduced risk for CI-AKI, although the effect size was small (OR \[95% CI\]: 0.74 \[0.57, 0.93\]). Alkalization with bicarbonate perfusion could theoretically reduce the formation of reactive oxygen species by decreasing the production of hydroxyl radicals due to inhibition of the Haber-Weiss and Fenton reactions \[[@B84]\]. However, the HYDRAREA study \[[@B12]\] assessed 307 critically ill patients with stable renal function and found that hydration with bicarbonate provided no benefit relative to hydration with isotonic sodium chloride. These researchers also noted that bicarbonate provided a greater benefit in the smaller studies, suggesting publication bias. Recently, Weisbord et al. \[[@B11]\] enrolled 5177 patients with high risk for renal complications and found that administration of sodium bicarbonate did not reduce the occurrence of CI-AKI. This result supports the interpretation that sodium bicarbonate is not more effective than sodium chloride in preventing CI-AKI or longer-term adverse outcomes after angiography. However, there was high heterogeneity among our 60 studies regarding concurrent medications, comorbidities (CHF, DM), types of CM, periprocedural hydration protocols, concentrations and dosages of sodium bicarbonate, and radiographic procedures \[[@B12]\]. Thus, we do not recommend alkalization with intravenous sodium bicarbonate as a single strategy, and a more effective hydration strategy is needed to prevent CI-AKI.

Several recent RCTs of high risk patients \[[@B13], [@B28], [@B47], [@B55]\] showed that furosemide-induced high-volume forced diuresis with matched hydration using the RenalGuard system effectively prevented CI-AKI. RenalGuard is a closed-loop fluid-management system, in which each volume of urine that enters the collection bag leads to the infusion of an equal volume of saline into the patient. Two meta-analyses \[[@B14], [@B16]\] of RCTs concluded that the RenalGuard system significantly reduced the risk of CI-AKI and the need for renal replacement therapy in high-risk patients undergoing coronary angiography. Our rankogram analysis indicated that the RenalGuard system of guided hydration had the highest rank, with a SUCRA of 0.974. However, we did not assess the effectiveness of intravenous hydration plus diuresis without a guided system, and the rankogram indicated that hemodynamic guided hydration was the second best method, with a SUCRA of 0.849. Brar et al. \[[@B17]\] used left ventricular end-diastolic pressure to guide fluid administration and demonstrated that this method was safe and effective in prevention of CI-AKI among patients undergoing cardiac catheterization. Another study \[[@B19]\] demonstrated that central venous pressure-guided fluid administration safely and effectively reduced the risk of CI-AKI in patients with CKD and CHF. Maioli et al. \[[@B18]\] assessed body fluid level using bioimpedance vector analysis (BIVA), which allows adjustment of intravascular volume expansion, and this led to a lower incidence of CI-AKI after angiographic procedures. Therefore, our results indicate that the RenalGuard system and hemodynamic guided hydration are best for patients with high-risk for CI-AKI, especially those with CKD and cardiac dysfunction.

5. Limitations {#sec5}
==============

It is essential to note several limitations of our study. Firstly, the hydration protocol should have a substantial influence on CI-AKI, but because of the high heterogeneity of specific protocols used in the included studies, we could not analyze distinct protocols, such as the effect of different concentrations of sodium bicarbonate, and the effect of hydration duration. Secondly, several confounding factors that we did consider may have impacted the effects of hydration, including dosage and types of CM, risk status of patients for CI-AKI, and other factors. Finally, it may be inappropriate to define hemodynamic guided hydration based on the use of different indexes, such as left ventricular end-diastolic pressure, central venous pressure, and bioimpedance.

6. Conclusion {#sec6}
=============

This Bayesian NMA provided substantial evidence to support the use of RenalGuard or hemodynamic guided hydration to prevent CI-AKI in high-risk patients, especially those with CKD or cardiac dysfunction.
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![Identification and selection of studies for Bayesian network meta-analysis.](JITC2020-7292675.001){#fig1}

![Network diagram of eight hydration strategies used to prevent contrast-induced acute kidney injury in the 60 included studies. Circles represent hydration strategies and lines represent direct comparisons. Circle size indicates the number of participants who received each treatment, and line thickness indicates the number of studies in each comparison.](JITC2020-7292675.002){#fig2}

![Forest plot showing the effect of different hydration strategies. Summary estimates from the pooled studies with 95% confidence intervals are indicated for fixed effects (open diamonds) and random effects (filled diamonds) models.](JITC2020-7292675.003){#fig3}

![League table, showing all pairwise comparisons of studies.](JITC2020-7292675.004){#fig4}

![Rankogram of the effect of different hydration strategies in reducing the risk of contrast-induced acute kidney injury.](JITC2020-7292675.005){#fig5}

![Inconsistency plot of enrolled studies, showing the posterior mean deviance of each study from the consistency model (horizontal axis) and the inconsistency model (vertical axis).](JITC2020-7292675.006){#fig6}

###### 

Characteristics of the included studies.

  Studies                                 Patients (*n*)   Inclusion criteria/risk of CI-AKI                                                                                                                                          Mean age (years)   Males (%)   Baseline SCr (mg/dL)   Baseline eGFR (mL/min/1.73 m^2^)   Mean LVEF (%)   DM (%)   HF (%)   Treatment groups        Types of CM                            CM dosage (mL)   Jadad score   No. of patients   Inclusion criteria/risk of CI-AKI                                                                                                                                          Mean age   Male (%)   Baseline SCr   Baseline eGFR   Mean LVEF   DM (%)   HF (%)   Groups                 Types of CM                              Dosage of CM   Jadad score
  --------------------------------------- ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ----------- ---------------------- ---------------------------------- --------------- -------- -------- ----------------------- -------------------------------------- ---------------- ------------- ----------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- ---------- -------------- --------------- ----------- -------- -------- ---------------------- ---------------------------------------- -------------- -------------
  Weisbord et al. \[[@B11]\]              4993             High risk for renal complications and scheduled for angiography                                                                                                            69.8               93.6        132.6                  50.2                                               80.9     7.4      SC vs. SB               Iodixanol or low-osmolar               85               5             4993              High risk for renal complications and scheduled for angiography                                                                                                            69.8       93.6       132.6          50.2                        80.9     7.4      SC vs. SB              Iodixanol or low-osmolar                 85             5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  van Mourik et al. \[[@B24]\]            74               Symptomatic aortic valve stenosis and impaired renal function who underwent pre-TAVI CTA                                                                                   82.9               44.6        104.3                  47.4                                               31.1              SC vs. SB               Iopromide                              90               3             74                Symptomatic aortic valve stenosis and impaired renal function who underwent pre-TAVI CTA                                                                                   82.9       44.6       104.3          47.4                        31.1              SC vs SB               Iopromide                                90             3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Saratzis et al. \[[@B25]\]              58               Elective EVAR for infrarenal AAA                                                                                                                                           75                 89.7                               65.5                                               13.8              SC vs. SB               Iomeprol                               126              3             58                Elective EVAR for infrarenal AAA                                                                                                                                           75         89.7                      65.5                        13.8              SC vs SB               Iomeprol                                 126            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Maioli et al. \[[@B18]\]                296              Elective coronary angiographic procedures                                                                                                                                  71                 68.2        89.3                                                      48              24.7              SC vs. HDy              Iodixanol                              131              3             296               Elective coronary angiographic procedures                                                                                                                                  71         68.2       89.3                           48          24.7              SC vs HDy              Iodixanol                                131            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Kooiman et al. \[[@B26]\]               333              CKD patients undergoing elective cardiovascular diagnostic or interventional contrast procedures                                                                           73                 64.6                               50.5                                               38.7     16.5     SC vs. SB               Not mentioned                          113              3             333               CKD patients undergoing elective cardiovascular diagnostic or interventional contrast procedures                                                                           73         64.6                      50.5                        38.7     16.5     SC vs SB               Not mentioned                            113            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Valette et al. \[[@B12]\]               307              Critically ill patients with stable renal function who received intravascular CM                                                                                           56.2               67.8        61.4                                                                      13.4     6.5      SC vs. SB               Low-osmolar                            90               4             307               Critically ill patients with stable renal function who received intravascular CM                                                                                           56.2       67.8       61.4                                       13.4     6.5      SC vs SB               Low-osmolar                              90             4
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Nijssen et al. \[[@B10]\]               660              High-risk patients with eGFR of 30--59 ml/min/1.73 m^2^, undergoing an elective procedure requiring CM administration                                                      72                 61.7        118                    47.4                                               32.6              Non vs. SC              Iopromide                              90.5             3             660               High-risk patients with eGFR of 30--59 ml/min/1.73 m^2^, undergoing an elective procedure requiring CM administration                                                      72         61.7       118            47.4                        32.6              Non vs SC              Iopromide                                90.5           3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Alonso et al. \[[@B27]\]                93               Patients receiving CM during CRT devices implantation                                                                                                                      66.5               65.3        110.5                                                     28.5            37                SC vs. SB               Iodixanol                              102              2             93                Patients receiving CM during CRT devices implantation                                                                                                                      66.5       65.3       110.5                          28.5        37                SC vs SB               Iodixanol                                102            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Usmiani et al. \[[@B28]\]               124              Coronary angiography/PCI with eGFR of less than 60 ml/min/1.73 m^2^                                                                                                        75                 74          130.8                  44                                 25              84                SC vs. RenalGuard       Iodixanol                              156              3             124               Coronary angiography/PCI with eGFR of less than 60 ml/min/1.73 m^2^                                                                                                        75         74         130.8          44              25          84                SC vs RenalGuard       Iodixanol                                156            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Turedi et al. \[[@B29]\]                172              Contrast-enhanced CTPA on suspicion of PE with at least one risk factor for CIN                                                                                            75.5               51.7        85.4                                                                                        SC vs. SB               Water-soluble, nonionic, low-osmolar   \<100            3             172               Contrast-enhanced CTPA on suspicion of PE with at least one risk factor for CIN                                                                                            75.5       51.7       85.4                                                         SC vs SB               Water-soluble, nonionic, low-osmolar     \<100          3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Qian et al. \[[@B19]\]                  264              CKD and CHF undergoing coronary procedures                                                                                                                                 63.5               74.6        151                    37.5                               39.5            47.3              SC vs. HDy              Iodixanol                              166              5             264               CKD and CHF undergoing coronary procedures                                                                                                                                 63.5       74.6       151            37.5            39.5        47.3              SC vs HDy              Iodixanol                                166            5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Solomon et al. \[[@B30]\]               391              Elective coronary or peripheral angiography with eGFR \<45 ml/min/1.73 m^2^                                                                                                72                 57.5        169.3                  32.8                                               59.1     35.5     SC vs. SB               Not mentioned                          107              4             391               Elective coronary or peripheral angiography with eGFR \<45 ml/min/1.73 m^2^                                                                                                72         57.5       169.3          32.8                        59.1     35.5     SC vs SB               Not mentioned                            107            4
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Martin-Moreno et al. \[[@B31]\]         130              Receiving CM for CT scan                                                                                                                                                   57.5               64.3        79.6                                                                                        Non vs SB               Not mentioned                          120              3             130               Receiving CM for CT scan                                                                                                                                                   57.5       64.3       79.6                                                         Non vs SB              Not mentioned                            120            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Jurado-Román et al. \[[@B32]\]          408              STEMI undergoing primary PCI                                                                                                                                               63.1               73.4                               89                                                 22.5     14.7     Non vs. SC              Iso-osmolar nonionic                   174              2             408               STEMI undergoing primary PCI                                                                                                                                               63.1       73.4                      89                          22.5     14.7     Non vs SC              Iso-osmolar nonionic                     174            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Barbanti et al. \[[@B13]\]              112              TAVR                                                                                                                                                                       81                 40.2        87.1                   51.5                               54.6            25                SC vs. RenalGuard       Buckinghamshire                        175              3             112               TAVR                                                                                                                                                                       81         40.2       87.1           51.5            54.6        25                SC vs RenalGuard       Buckinghamshire                          175            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Yeganehkhah et al. \[[@B33]\]           100              CAG                                                                                                                                                                        59.7               53          99.5                                                      43.8            39                SC vs. SB               Iohexol                                45.4             3             100               CAG                                                                                                                                                                        59.7       53         99.5                           43.8        39                SC vs SB               Iohexol                                  45.4           3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Yang et al. \[[@B34]\]                  320              Elective cardiovascular procedures including CAG or interventional treatment                                                                                               59.2               53.1        70.2                   93.1                               55.1            20                SC + NAC vs. SB + NAC   Iopromide                              125              3             320               Elective cardiovascular procedures including CAG or interventional treatment                                                                                               59.2       53.1       70.2           93.1            55.1        20                SC + NAC vs SB + NAC   Iopromide                                125            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Yang et al. \[[@B34]\]                  320              Elective cardiovascular procedures including CAG or interventional treatment                                                                                               59.2               53.1        70.2                   93.1                               55.1            20                SC vs. SB               Iopromide                              125              3             320               Elective cardiovascular procedures including CAG or interventional treatment                                                                                               59.2       53.1       70.2           93.1            55.1        20                SC vs SB               Iopromide                                125            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Thayssen et al. \[[@B35]\]              362              STEMI undergoing primary PCI within 12 hours from the onset of chest pain                                                                                                  62.5               78.5        77                     90.5                               50              9.7               SC vs. SB               Iodixanol                              140              5             362               STEMI undergoing primary PCI within 12 hours from the onset of chest pain                                                                                                  62.5       78.5       77             90.5            50          9.7               SC vs SB               Iodixanol                                140            5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Nieto-Rios et al. \[[@B36]\]            220              Tomography scan using CM or angiography                                                                                                                                    60                 57.7        115.8                                                                     37.3              SC vs. SB               Iohexol                                100              3             220               Tomography scan using CM or angiography                                                                                                                                    60         57.7       115.8                                      37.3              SC vs SB               Iohexol                                  100            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Manari et al. \[[@B37]\]                592              STEMI within 12 h from symptom onset referred for primary angioplasty                                                                                                      65                 74.8        88.5                   81                                 48              16.6     11.8     SC vs. SB               Iodixanol                              198              3             592               STEMI within 12 h from symptom onset referred for primary angioplasty                                                                                                      65         74.8       88.5           81              48          16.6     11.8     SC vs SB               Iodixanol                                198            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Mahmoodi et al. \[[@B38]\]              350              Coronary interventions                                                                                                                                                     64.48              51.4        103                    64.8                                                                 SC vs. SB               Iohexol                                                 2             350               Coronary interventions                                                                                                                                                     64.48      51.4       103            64.8                                          SC vs SB               Iohexol                                                 2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Luo et al. \[[@B39]\]                   216              STEMI                                                                                                                                                                      67                 65.7        77                     77.6                                               25                Non vs. SC              Iopamiron                              234.9            3             216               STEMI                                                                                                                                                                      67         65.7       77             77.6                        25                Non vs SC              Iopamiron                                234.9          3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Kooiman et al. \[[@B40]\]               548              CKD patients receiving CE-CT                                                                                                                                               72.1               60.4                               50.4                                               26.8     16.4     SC vs. SB               Iomeprol                               105              5             548               CKD patients receiving CE-CT                                                                                                                                               72.1       60.4                      50.4                        26.8     16.4     SC vs SB               Iomeprol                                 105            5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Kooiman et al. \[[@B41]\]               138              CKD patients receiving CTPA                                                                                                                                                70.5               50                                 49.2                                               16.7     8        Non vs. SB              Iopromide or iobitridol or iodixanol   74               5             138               CKD patients receiving CTPA                                                                                                                                                70.5       50                        49.2                        16.7     8        Non vs SB              Iopromide, or iobitridol, or iodixanol   74             5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Brar et al. \[[@B17]\]                  396              Referred to the cardiac catheterization laboratory with eGFR ≤ 60 mL/min/1.73 m^2^, and at least one of the following: DM, CHF, hypertension, or age older than 75 years   72                 61.9        123.8                  48                                                 51.3     20.5     SC vs. HDy              Ioxilan                                108              3             396               Referred to the cardiac catheterization laboratory with eGFR ≤ 60 mL/min/1.73 m^2^, and at least one of the following: DM, CHF, hypertension, or age older than 75 years   72         61.9       123.8          48                          51.3     20.5     SC vs HDy              Ioxilan                                  108            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Akyuz et al. \[[@B42]\]                 225              At least one of the high-risk factors for developing CI-AKI and undergoing CAG and/or PCI                                                                                  63.4               68.9        79.6                   84.5                               47.5            60.9     7.6      Oral vs. SC             Not mentioned                          108              2             225               At least one of the high-risk factors for developing CI-AKI and undergoing CAG and/or PCI                                                                                  63.4       68.9       79.6           84.5            47.5        60.9     7.6      Oral vs SC             Not mentioned                            108            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Kristeller et al. \[[@B43]\]            92               Stage 3 or higher CKD who underwent cardiac surgery using CPB                                                                                                              72.5               57.6        119.1                                                                     44.6     34.8     SC vs SB                Not mentioned                          79               5             92                Stage 3 or higher CKD who underwent cardiac surgery using CPB                                                                                                              72.5       57.6       119.1                                      44.6     34.8     SC vs SB               Not mentioned                            79             5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Koc et al. \[[@B44]\]                   195              DM patients                                                                                                                                                                62                 52.3        88.4                                                                      100               SC vs. SB               Not mentioned                          90               4             195               DM patients                                                                                                                                                                62         52.3       88.4                                       100               SC vs SB               Not mentioned                            90             4
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Gu et al. \[[@B45]\]                    859              Coronary angiography or angioplasty                                                                                                                                        59                 72.2        90.1                   74.2                                               20.6     0.6      SC vs. SC + diuresis    Not mentioned                          100              2             859               Coronary angiography or angioplasty                                                                                                                                        59         72.2       90.1           74.2                        20.6     0.6      SC vs SC + diuresis    Not mentioned                            100            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Boucek et al. \[[@B46]\]                120              Diabetic patients with impaired renal function, undergoing intra-arterial or intravenous use of CM                                                                         65                 75          165                    44.1                                               100               SC vs. SB               Low-osmolar nonionic iodinated         110              5             120               Diabetic patients with impaired renal function, undergoing intra-arterial or intravenous use of CM                                                                         65         75         165            44.1                        100               SC vs SB               Low-osmolar nonionic iodinated           110            5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Marenzi et al. \[[@B47]\]               170              CKD undergoing coronary procedures                                                                                                                                         73                 78.2        154.7                  39                                 51.5            36.4              SC vs. RenalGuard       Iomeprol                               170              3             170               CKD undergoing coronary procedures                                                                                                                                         73         78.2       154.7          39              51.5        36.4              SC vs RenalGuard       Iomeprol                                 170            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Kong et al. \[[@B48]\]                  80               Definitive or suspected coronary artery disease                                                                                                                            56.5               53.8        105                                                                       23.8              Oral vs. SC             Iopromide                              152              3             80                Definitive or suspected coronary artery disease                                                                                                                            56.5       53.8       105                                        23.8              Oral vs SC             Iopromide                                152            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Klima et al. \[[@B49]\]                 258              Renal insufficiency undergoing intravascular contrast procedures                                                                                                           77                 64          137                    43.6                                               37       44       SC vs. SB               Not mentioned                          100              5             258               Renal insufficiency undergoing intravascular contrast procedures                                                                                                           77         64         137            43.6                        37       44       SC vs SB               Not mentioned                            100            5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Gomes et al. \[[@B50]\]                 301              Patients at moderate to high risk for developing CIN who were referred for elective CAG or PCI                                                                             64                 47.5        132.6                                                                     18.9              SC vs. SB               Not mentioned                          125              2             301               Patients at moderate to high risk for developing CIN who were referred for elective CAG or PCI                                                                             64         47.5       132.6                                      18.9              SC vs SB               Not mentioned                            125            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Motohiro et al. \[[@B51]\]              155              eGFR \<60 ml/min/1.73 m^2^ who were undergoing coronary angiography                                                                                                        72.5               69.7        136.6                  44.3                               55              60                SC vs. SB               Iopamidol                              135              3             155               eGFR \<60 ml/min/1.73 m^2^ who were undergoing coronary angiography                                                                                                        72.5       69.7       136.6          44.3            55          60                SC vs SB               Iopamidol                                135            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Maioli et al. \[[@B52]\]                300              STEMI undergoing primary PCI                                                                                                                                               65                 25          95.9                                                      42.5            21.7     24       Non vs. SB              Iodixanol                              216              3             300               STEMI undergoing primary PCI                                                                                                                                               65         25         95.9                           42.5        21.7     24       Non vs SB              Iodixanol                                216            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Lee et al. \[[@B53]\]                   382              Diabetic patients with renal disease (serum creatinine \>1.1 mg/dl and eGFR \<60 ml/min/1.73 m^2^)                                                                         68                 70.9        132.6                  46                                                 100               SC vs. SB               Iodixanol                              116.5            3             382               Diabetic patients with renal disease (serum creatinine \>1.1 mg/dl and eGFR \<60 ml/min/1.73 m^2^)                                                                         68         70.9       132.6          46                          100               SC vs SB               Iodixanol                                116.5          3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Hafiz et al. \[[@B54]\]                 320              Patients with baseline renal insufficiency scheduled to undergo catheterization                                                                                            73                 56.9        141.4                                                                     47.2              SC vs. SB               Nonionic, low-osmolar                  115              3             320               Patients with baseline renal insufficiency scheduled to undergo catheterization                                                                                            73         56.9       141.4                                      47.2              SC vs SB               Nonionic, low-osmolar                    115            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Briguori et al. \[[@B55]\]              292              High-risk patients with an eGFR ≤30 ml/min/1.73 m^2^ and/or a risk score ≥11                                                                                               76                 65.4        158.7                  32                                 47              70.2     28.4     SB vs. RenalGuard       Iodixanol                              140              3             292               High-risk patients with an eGFR ≤30 ml/min/1.73 m^2^ and/or a risk score ≥11                                                                                               76         65.4       158.7          32              47          70.2     28.4     SB vs RenalGuard       Iodixanol                                140            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Wróbel et al. \[[@B56]\]                102              Coronary angiography and/or angioplasty, and had comorbidities that increase the risk of CIN                                                                               65.5               56.9        236.4                                                                                       Oral vs. SC             Loversol                               69.5             2             102               Coronary angiography and/or angioplasty, and had comorbidities that increase the risk of CIN                                                                               65.5       56.9       236.4                                                        Oral vs SC             Loversol                                 69.5           2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Vasheghani-Farahani et al. \[[@B57]\]   72               CAG, with SCr 1.5 mg/dL within 2 weeks, having at least 1 of the risk factors                                                                                              62                 79.2        151.2                  44.2                               36.1            34.7     45.8     0.45 SC vs. SB          Iohexol                                117.5            3             72                CAG, with SCr 1.5 mg/dL within 2 weeks, having at least 1 of the risk factors                                                                                              62         79.2       151.2          44.2            36.1        34.7     45.8     0.45 SC vs SB          Iohexol                                  117.5          3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Cho et al. \[[@B58]\]                   91               Undergoing an elective CAG                                                                                                                                                 78                 50.5        123                                                                       38.5     17.6     SC vs. SB               Isoversol                              128              2             91                Undergoing an elective CAG                                                                                                                                                 78         50.5       123                                        38.5     17.6     SC vs SB               Isoversol                                128            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Vasheghani-Farahani et al. \[[@B59]\]   265              Serum creatinine level of 1.5 mg/dL or greater undergoing elective CAG                                                                                                     63.3               83          145.4                  45.9                               51.7            21.5              SC vs. SB               Iohexol                                114              5             265               Serum creatinine level of 1.5 mg/dL or greater undergoing elective CAG                                                                                                     63.3       83         145.4          45.9            51.7        21.5              SC vs SB               Iohexol                                  114            5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Tamura et al. \[[@B60]\]                144              Scheduled for elective CAG or PCI                                                                                                                                          72.8               87.5        121.1                  39.1                               57.8            58.3              SC vs. SB               Iohexol                                85               3             144               Scheduled for elective CAG or PCI                                                                                                                                          72.8       87.5       121.1          39.1            57.8        58.3              SC vs SB               Iohexol                                  85             3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Pakfetrat et al. \[[@B61]\]             192              Undergoing elective CAG or PCI                                                                                                                                             57.9               61.5        97.2                   72.2                               50.5            29.7     5.2      SC vs. SB               Iodixanol                              65               4             192               Undergoing elective CAG or PCI                                                                                                                                             57.9       61.5       97.2           72.2            50.5        29.7     5.2      SC vs SB               Iodixanol                                65             4
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Haase et al. \[[@B62]\]                 100              At increased risk of postoperative acute renal dysfunction who were scheduled for elective or urgent cardiac surgery necessitating the use of CPB                          71                 66          90.7                                                                                        SC vs. SB               Not mentioned                                           5             100               At increased risk of postoperative acute renal dysfunction who were scheduled for elective or urgent cardiac surgery necessitating the use of CPB                          71         66         90.7                                                         SC vs SB               Not mentioned                                           5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Budhiraja et al. \[[@B63]\]             187              Nonemergent CAG, baseline serum creatinine \>1.0 mg/dL, and availability of serum creatinine values at days 1--3                                                           68                             125.8                  57.2                                               30.5              SC vs. SB               Iopromide                              199              2             187               Nonemergent CAG, baseline serum creatinine \>1.0 mg/dL, and availability of serum creatinine values at days 1--3                                                           68                    125.8          57.2                        30.5              SC vs SB               Iopromide                                199            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Angoulvant et al. \[[@B64]\]            201              Scheduled for elective CAG, with or without PTCA with a baseline SCr \< 140 *μ*mol/L                                                                                       62                 80.6        86.2                                                                                        Oral vs. SC             Not mentioned                          290              3             201               Scheduled for elective CAG, with or without PTCA with a baseline SCr\< 140 *μ*mol/L                                                                                        62         80.6       86.2                                                         Oral vs SC             Not mentioned                            290            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Maioli et al. \[[@B65]\]                502              Undergoing coronary angiographic procedures with estimated creatinine clearance \<60 ml/min                                                                                74                 59          107                                                       46.5            59.1              SC vs. SB               Iodixanol                              165              3             502               Undergoing coronary angiographic procedures with estimated creatinine clearance \<60 ml/min                                                                                74         59         107                            46.5        59.1              SC vs SB               Iodixanol                                165            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Chen et al. \[[@B66]\]                  660              Myocardial ischemia (angina or positive exercise treadmill) scheduled for PCI, with SCr\<1.5 mg/dl                                                                         60                 85          114.9                                                     54              8                 Non vs. SC              Iso-osmolar nonionic                   285              2             660               Myocardial ischemia (angina or positive exercise treadmill) scheduled for PCI, with SCr \< 1.5 mg/dl                                                                       60         85         114.9                          54          8                 Non vs SC              Iso-osmolar nonionic                     285            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Chen et al. \[[@B66]\]                  276              Myocardial ischemia (angina or positive exercise treadmill) scheduled for PCI, with SCr ≥ 1.5 mg/dl                                                                        63                 82          221                                                       41              22                Non vs. SC              Iso-osmolar nonionic                   298              2             276               Myocardial ischemia (angina or positive exercise treadmill) scheduled for PCI, with SCr ≥ 1.5 mg/dl                                                                        63         82         221                            41          22                Non vs SC              Iso-osmolar nonionic                     298            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Brar et al. \[[@B67]\]                  353              Patients with stable renal disease and undergoing CAG                                                                                                                      71                 63.9        131.7                  48                                 57              44.5     27.2     SC vs. SB               Ioxilan                                132              5             353               Patients with stable renal disease and undergoing CAG                                                                                                                      71         63.9       131.7          48              57          44.5     27.2     SC vs SB               Ioxilan                                  132            5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Adolph et al. \[[@B68]\]                145              Stable renal insufficiency and undergoing elective diagnostic or interventional coronary angiography                                                                       72.6               77.9        132.6                                                                     33.8              SC vs. SB               Iodixanol                              140              5             145               Stable renal insufficiency and undergoing elective diagnostic or interventional coronary angiography                                                                       72.6       77.9       132.6                                      33.8              SC vs SB               Iodixanol                                140            5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Schmidt et al. \[[@B69]\]               96               CAG                                                                                                                                                                        67.6               74          146.7                                                                     64.6              SC vs. SB               Optiray                                186              2             96                CAG                                                                                                                                                                        67.6       74         146.7                                      64.6              SC vs SB               Optiray                                  186            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Ozcan et al. \[[@B70]\]                 264              Scheduled for CAG or PCI and had a baseline creatinine level \>1.2 mg/dL                                                                                                   69                 74.6        122.9                                                                     45.1     26.5     SC vs. SB               Ioxaglate                              110              2             264               Scheduled for CAG or PCI and had a baseline creatinine level \>1.2 mg/dL                                                                                                   69         74.6       122.9                                      45.1     26.5     SC vs SB               Ioxaglate                                110            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Masuda et al. \[[@B71]\]                59               Scheduled to undergo an emergency coronary angiography or intervention                                                                                                     75                 44.1        116.2                                                                     30.5              SC vs. SB               Iopamidol                              116              3             59                Scheduled to undergo an emergency coronary angiography or intervention                                                                                                     75         44.1       116.2                                      30.5              SC vs SB               Iopamidol                                116            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Dussol et al. \[[@B72]\]                156              CKD, who were undergoing radiological procedures with CM                                                                                                                   65                 67.9        204.5                  33.1                                               28.8     16       SC vs. SC + diuresis    Nonionic, low osmolar                  117              5             156               CKD, who were undergoing radiological procedures with CM                                                                                                                   65         67.9       204.5          33.1                        28.8     16       SC vs SC + diuresis    Nonionic, low osmolar                    117            5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Mueller et al. \[[@B73]\]               425              Scheduled for elective or emergency PCI                                                                                                                                    64                 75                                 89                                                 16                0.45 SC vs. SC          Iopromide                              226              2             425               Scheduled for elective or emergency PCI                                                                                                                                    64         75                        89                          16                0.45 SC vs SC          Iopromide                                226            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Merten et al. \[[@B74]\]                119              Stable renal insufficiency undergoing diagnostic or interventional procedures requiring radiographic contrast, SCr\> 1.1 mg/dL                                             68                 74.8        159.1                                                                     47.9              SC vs. SB               Iopamidol                              132              3             119               Stable renal insufficiency undergoing diagnostic or interventional procedures requiring radiographic contrast, SCr\> 1.1 mg/dL                                             68         74.8       159.1                                      47.9              SC vs SB               Iopamidol                                132            3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Trivedi et al. \[[@B75]\]               53               Scheduled to undergo nonemergency CAG                                                                                                                                      67.9               98.1        106.4                                                     52.1            18.9              Oral vs. SC             Ionic, low-osmolar                     148              2             53                Scheduled to undergo nonemergency CAG                                                                                                                                      67.9       98.1       106.4                          52.1        18.9              Oral vs SC             Ionic, low-osmolar                       148            2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Mueller et al. \[[@B76]\]               1383             Scheduled for elective or emergency CAG                                                                                                                                    64                 74.4        81.77                                                                     15.7              0.45 SC vs. SC          Ultravist or imeron                    234              2             1383              Scheduled for elective or emergency CAG                                                                                                                                    64         74.4       81.77                                      15.7              0.45 SC vs SC          Ultravist, or imeron                     234            2

CI-AKI: contrast-induced acute kidney injury; SCr: serum creatinine; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; DM: diabetes mellitus; HF: heart failure; CM: contrast media; CTA: computed tomography angiography; TAVI: transcatheter aortic valve implantation; EVAR: elective endovascular aneurysm repair; AAA: abdominal aortic aneurysm; CKD: chronic kidney disease; CRT: cardiac resynchronization therapy; CTPA: computed tomography pulmonary angiography; PE: pulmonary embolism; CIN: contrast-induced nephropathy; CHF: chronic heart failure; CT: computed tomography; TAVR: transcatheter aortic valve replacement; CAG: coronary angiography; CE-CT: contrast media-enhanced computed tomography; CPB: cardiopulmonary bypass; PTCA: percutaneous transluminal coronary angioplasty; NAC: N-acetylcysteine. Treatment groups: SC: intravenous 0.9% sodium chloride; SB: intravenous sodium bicarbonate; Non: nonhydration; Oral: oral hydration; RenalGuard: RenalGuard system; HDy: hemodynamic guided hydration; SC + diuresis: intravenous 0.9% sodium chloride + diuresis; 0.45 SC: 0.45% sodium chloride.
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